SMARCB1 and central nervous system neoplasm: Only a subset of pediatric CNS tumors will harbor canonical driver mutations (e.g. in Histone 3, BRAF, NTRK, SMARCB1) and the catalog of prognostic molecular findings is constantly evolving.